Californian company Ideaya Biosciences (Nasdaq: IDYA) has agreed a strategic partnership with UK pharma major GlaxoSmithKline (LSE: GSK) in synthetic lethality, an emerging field in oncology.
The partnership includes Ideaya's synthetic lethality programs MAT2A, Pol Theta and Werner Helicase, which are projected to reach clinical trials within the next three years.
Ideaya has solved the crystal structures for all three of these, enabling structure-based drug design, and has demonstrated in vivo proof-of-concept in relevant animal models for its MAT2A and Pol Theta programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze